By Inside Your Peptides · Originally published · Language revised 2026-09-17
Approval, compounding eligibility, import policy and research labeling are separate questions. A shortage-list change or RUO disclaimer does not settle every seller's legal status, and current claims need exact dated agency documents.
Four questions that should stay separate
Is a specific product approved for a specific use? Can a substance be used in compounding under the relevant law? Does an import policy apply to that product and firm? What does the seller's intended-use evidence show? One answer does not settle the other three.
A label is not the entire legal analysis
In its August 2026 Peptide Partners warning letter, FDA evaluated website claims and products sold together despite research-use language. That letter illustrates an enforcement position for a named business; it is not a universal legal judgment about every research supplier.
Read updates with dates and jurisdiction
Use the exact agency decision, warning letter, shortage determination or import-alert entry. State when it was checked and what it covers. This explainer does not offer legal advice or describe a research disclaimer as permission for human use. Qualified legal review is needed for a business's specific situation.
Sources used in this revision
- FDA · Peptide Partners warning letter, 24 August 2026 · Checked 17 September 2026
- FDA · Drug registration and listing · Checked 17 September 2026
- FDA · Import Alert 66-80 · Checked 17 September 2026
Educational reading only. This page does not provide medical, dosing or personal-use guidance.